Endocrine Abstracts

Introduction: VIPomas are rare neuroendocrine tumors (NET), usually located in the pancreas that secrete vasoactive intestinal polypeptide (VIP) leading to high-volume watery diarrhea and complications such as hypokalemia, acidosis and dehydration. The management of VIPoma symptoms is often challenging when surgical resection of all the lesions is not feasible. Treatments are then based on somatostatin analogs (SSA) and may also include hepatic chemoembolization, systemic chem...

Introduction: Regorafenib, a Tyrosine kinase inhibitor (TKI) recently approved for the treatment of metastatic colorectal cancer patients previously treated with fluoropyrimidine-based chemotherapy, VEGF and EGFR inhibitors, may, like others TKIs produce hypothyroidism, but this effect has not been systematically evaluated so far.Description of methods: Prospective evaluation of thyroid function, autoimmunity and morphology during treatment with Regorafe...

The relationship between papillary thyroid cancer (PTC) and autoimmune thyroiditis remains controversial. To gain mechanistic insights, we developed a mouse model by combining three strains: BRAFv600E knock-in and TPO-CRE-ER transgenic to induce PTC upon tamoxifen injection, and NOD.H2h4 congenic to induce thyroiditis upon iodine administration.A total of 113 mice of the desired genotype (BRAF mutant homozygous, CRE transgenic hemiz...

Background: The development of thyroid dysfunction is a frequent side effect associated to sunitinib therapy but scanty data are available on thyroid function on long-term sunitinib-treated patients.Objective: Prospective evaluation of 28 patients suffering from mRCC treated with sunitinib, enrolled between September 2013 and October 2015. 28 patients (24 men and 3 women (median age 57.7, range 51–77)) with comparable tumor staging, normal thyroid f...

Background: Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown.Objective: To evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs. <p class="abste...

Background: Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown.Objective: To evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs.<p class="abstex...